ClinicalTrials.gov
public full text
Public Domain
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
This phase I trial finds the best dose and side effects of cabozantinib and pamiparib in treating patients with solid tumors that have spread to other places in the body (advanced) or does not respond to treatment (refractory). Cabozantinib and pamiparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors#1060314
- Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer#911442
- Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases#1163590
- Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas#1033620
- Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure#1031111
Record · ID 887000
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive